Malaizija - anglų - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

zuellig pharma sdn bhd - buprenorphine hydrochloride -

Airija - anglų - HPRA (Health Products Regulatory Authority)

rb pharmaceuticals limited - buprenorphine hydrochloride - tablet sublingual - 0.2 base milligrams - buprenorphine

Australija - anglų - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - buprenorphine hydrochloride, quantity: 324 microgram/ml (equivalent: buprenorphine, qty 300 microgram/ml) - injection, solution - excipient ingredients: glucose monohydrate; hydrochloric acid; water for injections - temgesic injection is indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic injection should be employed when sublingual administration is not practical e.g. pre- or peri-operatively. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

reckitt benckiser (new zealand) limited - buprenorphine hydrochloride 0.216mg equivalent to 0.2 mg buprenorphine; naloxone hydrochloride dihydrate 0.2mg equivalent to 0.171 mg naloxone base - sublingual tablet - active: buprenorphine hydrochloride 0.216mg equivalent to 0.2 mg buprenorphine naloxone hydrochloride dihydrate 0.2mg equivalent to 0.171 mg naloxone base excipient: citric acid monohydrate lactose monohydrate magnesium stearate maize starch mannitol povidone sodium citrate dihydrate

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - buprenorphine hydrochloride 0.324 mg/ml equivalent to 0.3 mg/ml buprenorphine; buprenorphine hydrochloride 0.324 mg/ml equivalent to buprenorphine 0.3 mg/ml - solution for injection - 0.3 mg/ml - active: buprenorphine hydrochloride 0.324 mg/ml equivalent to 0.3 mg/ml buprenorphine excipient: glucose hydrochloric acid water for injection active: buprenorphine hydrochloride 0.324 mg/ml equivalent to buprenorphine 0.3 mg/ml excipient: glucose monohydrate hydrochloric acid water for injection - temgesic injection is indicated for the short-term (not more than one week) management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. temgesic is not recommended for use in children. temgesic does not have an approved role in opioid dependence rehabilitation programmes.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

reckitt benckiser pty ltd - buprenorphine hydrochloride -

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

reckitt benckiser (new zealand) limited - buprenorphine hydrochloride 0.216mg equivalent to 0.2 mg buprenorphine - sublingual tablet - 0.2 mg - active: buprenorphine hydrochloride 0.216mg equivalent to 0.2 mg buprenorphine

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

eumedica pharmaceuticals ag - buprenorphine hydrochloride - solution for injection - 300microgram/1ml

Airija - anglų - HPRA (Health Products Regulatory Authority)

rb pharmaceuticals limited - buprenorphine hydrochloride - solution for injection - 300 microgram(s)/millilitre - oripavine derivatives; buprenorphine

Airija - anglų - HPRA (Health Products Regulatory Authority)

indivior europe limited - buprenorphine hydrochloride - solution for injection - 300 microgram(s)/millilitre - oripavine derivatives; buprenorphine